Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
ENTA Stock Chart & Stats
$12.61
-$0.16(-2.97%)
At close: 4:00 PM EST
$12.61
-$0.16(-2.97%)
Day’s Range― - ―
52-Week Range$4.09 - $17.15
Previous CloseN/A
Volume330.58K
Average Volume (3M)342.64K
Market Cap
$363.96M
Enterprise Value$268.11M
Total Cash (Recent Filing)$204.11M
Total Debt (Recent Filing)$207.10M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Feb 09, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding28,862,600
10 Day Avg. Volume434,456
30 Day Avg. Volume342,637
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.95
Price to Sales (P/S)3.91
P/FCF Ratio-7.94
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue4.14
Enterprise Value/Gross Profit4.14
Enterprise Value/Ebitda-3.25
Forecast
1Y Price Target
$18.50Price Target Upside46.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyPhase 2b results for zelicapavir demonstrated shorter symptom duration together with robust virologic and safety outcomes in high-risk adults, supporting confidence in a pivotal trial pathway.
Pediatric EfficacyPhase 2 pediatric data indicated faster symptom resolution with zelicapavir in children with respiratory syncytial virus, suggesting broader clinical utility across age groups.
Pipeline ExpansionAddition of multiple immunology programs targeting MRGPRX2 plus development of a second oral antiviral broaden the company's therapeutic footprint across respiratory and chronic inflammatory diseases.
Bears Say
Funding And Partner DependencyUncertainty about whether a development partner is required to initiate a pivotal trial could delay trial start or force reliance on external funding for late-stage development.
Phase 3 Execution RiskProgression to a Phase 3 study may depend on securing a partner if regulatory feedback does not support company-funded initiation, raising execution and timeline risk.
Enanta Pharmaceuticals News
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $4.09 and its highest was $17.15 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Enanta Pharmaceuticals’s market cap is $363.96M.
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Feb 09, 2026 which is in 21 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Nov 17, 2025. The company reported -$0.87 earnings per share for the quarter, beating the consensus estimate of -$1.021 by $0.151.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -0.77.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 28,862,600 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$0.87 in its last earnings report, beating expectations of -$1.021. Following the earnings report the stock price went down -3.588%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Currently, no hedge funds are holding shares in ENTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enanta Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.50 (46.71% Upside)
$18.50 (46.71% Upside)
Blogger Sentiment
Bullish
ENTA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 18.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $185.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.12%
12-Months-Change
Fundamentals
Return on Equity
-84.63%
Trailing 12-Months
Asset Growth
-25.10%
Trailing 12-Months
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
ENTA Stock 12 Month Forecast
Average Price Target
$18.50
▲(46.71% Upside)
Technical Analysis
Abeona Therapeutics
―
Tectonic Therapeutic
―
Allogene Therapeutics
―
Jade Biosciences
―
Neumora Therapeutics, Inc.
―
Ownership Overview
5.01% Insiders
9.37% Mutual Funds
0.28% Other Institutional Investors
74.36% Public Companies and
Individual Investors